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background: Percutaneous ventricular assist devices (PVADs) offer an important but resource-intensive option for management of cardiogenic 
shock (CS). Optimal selection of patients (pts) for PVAD support remains undefined. We investigated clinical characteristics associated with survival 
in pts receiving PVAD support.
Methods: We evaluated pts undergoing implantation of TandemHeart PVAD for CS at a US academic tertiary center. Between 2006 and 2013, 58 
consecutive pts were included, 35 with ischemic and 23 with non-ischemic cardiomyopathy (niCMP). Demographic, lab, hemodynamic, and survival 
data were collected as part of routine care.
results: Thirty pts (52%) survived to hospital discharge. Factors associated with survival to discharge included niCMP (78.3% vs. 34.3%; p=0.001; 
6 mo survival in Fig 1); younger age (47y ± 16 vs. 61y ± 11; p<0.001); and lower presenting EF (Fig 2, p=0.018). When stratified by EF, etiology of 
CMP was a stronger predictor of survival (Fig 2). Survivors also tended toward shorter durations of preceding intra-aortic balloon pump support 
(9:57h ± 8:41 vs. 30:06h ± 37:03; p=0.057). Notably, baseline hemodynamic and laboratory data, and the absence of biventricular failure were not 
significantly associated with survival.
conclusion: Pts in CS with niCMP, younger age, and lower EF prior to PVAD implantation were more likely to survive, with niCMP being most 
predictive. The optimal duration of intra-aortic balloon support prior to PVAD implantation warrants investigation.
 
